Trial reportBritish journal of cancer2006
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Trial report in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Guideline
- Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.Neoplasia (New York, N.Y.) · 2014Trial
- Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximated genetic subtypes.Journal of radiation research · 2013Trial
- Triple-negative breast cancer: multipronged approach, single-arm pilot phase II study.Cancer medicine · 2012Trial
- L-arginine dependence of breast cancer - molecular subtypes matter.BMC cancer · 2025Article
- Assessment ofAging · 2019Article
- An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.Frontiers in medicine · 2018Review
- Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.Journal of Cancer · 2018Article
- Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.PloS one · 2015Article
- Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).Biomedical reports · 2014Article
- A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences.Molecular oncology · 2013Article
- Differential network analysis applied to preoperative breast cancer chemotherapy response.PloS one · 2013Article
- Free circulating tumor DNA as a diagnostic marker for breast cancer.Journal of clinical laboratory analysis · 2012Article
- Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2012Review
- Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.Pathology oncology research : POR · 2012Article
- Basal breast cancer: a complex and deadly molecular subtype.Current molecular medicine · 2012Review
- Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.The American journal of pathology · 2011Review
- Article
- The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities.International journal of proteomics · 2011Article
- Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.Breast cancer research and treatment · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benefit from chemotherapy treatment in breast cancer patients is determined by the molecular make-up of the tumour. In a retrospective analysis, we determined the molecular subtypes of breast cancer originally defined by expression microarrays by immunohistochemistry in tumours of patients who took part in a randomised study of adjuvant high-dose chemotherapy in breast cancer. In addition, the topoisomerase II alpha (TOP2A) amplification status was determined by fluorescence in situ hybridisation and chromogenic in situ hybridisation. 411 of the 753 tumours (55%) were classified as luminal-like, 137 (18%) as basal-like and 205 (27%) as human epithelial receptor type 2 (HER2) amplified. The basal-like tumours were defined as having no expression of ER and HER2; 98 of them did express epidermal growth factor receptor and/or cytokeratin 5/6. The luminal-like tumours had a significantly better recurrence free and overall survival than the other two groups. From the 194 HER2-positive tumours, 47 (24%) were shown to harbour an amplification of TOP2A. Patients with an HER2-amplified tumour randomised to the high-dose therapy arm did worse than those in the conventional treatment arm, possibly caused by the lower cumulative anthracycline dose in the high-dose arm. The tumours with a TOP2A amplification contributed hardly to this difference, suggesting that TOP2A amplification is not the cause of the steep dose-response curve for anthracyclines in breast cancer. Possibly, the difference of the cumulative dose of only 25% between the treatment arms was insufficient to yield a survival difference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.